Accretion Nutraveda Ltd
Incorporated in 2021, Accretion Nutraveda is engaged in the manufacturing of Ayurvedic and Nutraceutical products in various dosage forms.[1]
- Market Cap ₹ 238 Cr.
- Current Price ₹ 329
- High / Low ₹ 348 / 150
- Stock P/E 32.1
- Book Value ₹ 55.5
- Dividend Yield 0.00 %
- ROCE 27.7 %
- ROE 25.0 %
- Face Value ₹ 10.0
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 35.0%
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Debtor days have increased from 60.3 to 88.1 days.
- Working capital days have increased from 111 days to 196 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE SME IPO
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|
| 2.89 | 5.01 | 16.00 | 33.59 | 48.98 | |
| Sales growth | +73.36% | +219.36% | +109.94% | +96.63% | |
| 2.27 | 3.78 | 12.29 | 26.70 | 39.31 | |
| Operating Profit | 0.62 | 1.23 | 3.71 | 6.89 | 9.67 |
| OPM % | 21.45% | 24.55% | 23.19% | 20.51% | 19.74% |
| 0.17 | 0.19 | 0.01 | 0.11 | 0.27 | |
| Interest | 0.19 | 0.24 | 0.35 | 0.53 | 0.68 |
| Depreciation | 0.31 | 0.26 | 0.22 | 0.26 | 0.27 |
| Profit before tax | 0.29 | 0.92 | 3.15 | 6.21 | 8.99 |
| Tax % | 3.45% | 9.78% | 20.63% | 18.36% | |
| 0.28 | 0.82 | 2.50 | 5.07 | 7.42 | |
| EPS in Rs | 0.78 | 2.28 | 5.10 | 7.00 | 10.25 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 127% |
| TTM: | 97% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 163% |
| TTM: | 83% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 35% |
| Last Year: | 25% |
Balance Sheet
Figures in Rs. Crores
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|
| Equity Capital | 0.36 | 0.36 | 0.49 | 7.24 | 7.24 |
| Reserves | -0.10 | 0.72 | 4.56 | 28.23 | 32.96 |
| 1.97 | 2.17 | 3.86 | 4.23 | 8.05 | |
| 1.83 | 1.39 | 1.63 | 2.08 | 2.00 | |
| Total Liabilities | 4.06 | 4.64 | 10.54 | 41.78 | 50.25 |
| 1.49 | 1.28 | 1.83 | 1.66 | 4.92 | |
| CWIP | 0.00 | 0.10 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 2.57 | 3.26 | 8.71 | 40.12 | 45.33 | |
| Total Assets | 4.06 | 4.64 | 10.54 | 41.78 | 50.25 |
Cash Flows
Figures in Rs. Crores
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| 0.68 | 0.23 | -2.22 | -9.42 | |
| -0.01 | -0.16 | -0.87 | -14.50 | |
| -0.63 | -0.04 | 2.98 | 25.19 | |
| Net Cash Flow | 0.04 | 0.03 | -0.10 | 1.26 |
| Free Cash Flow | 0.67 | 0.07 | -3.09 | -15.45 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 110% | 27% | -42% | -113% |
Ratios
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Debtor Days | 101.04 | 18.21 | 74.60 | 88.13 |
| Inventory Days | 279.12 | 303.74 | 158.50 | 136.10 |
| Days Payable | 354.26 | 113.58 | 30.73 | 11.35 |
| Cash Conversion Cycle | 25.89 | 208.37 | 202.36 | 212.87 |
| Working Capital Days | 8.84 | 7.29 | 128.89 | 195.59 |
| ROCE % | 42.34% | 57.57% | 27.73% |
Insights
In beta| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Capacity Utilization - Capsule % |
|
|||
| Capacity Utilization - Tablet % |
||||
| Customer Concentration - Top 5 Customers % of Total Sales |
||||
| Geographic Concentration - Gujarat % of Total Sales |
||||
| Production Volume - Capsule Numbers |
||||
| Production Volume - Tablet Numbers |
||||
| Number of Formulations (Product Portfolio) Number of formulations |
||||
| Order Book Value ₹ |
||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Investor Presentation
- Investor/Analysts Presentation for the Half Year ended on 30th September, 2026
-
Intimation For Change Of Corporate Identification Number (CIN) Of The Company.
- MCA updated the company’s CIN from L24290GJ2021PLC121216 to L21003GJ2021PLC121216.
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
- Accretion Nutraveda reported H1 FY27 revenue of Rs 29.44 crore and PAT of Rs 4.73 crore.
-
Board Meeting Outcome for Outcome Of The Board Meeting Dated 31St October, 2026
- Board approved H1 FY2026 unaudited results; profit rose to Rs 472.81 lakh, IPO funds 100% utilized.
-
Board Meeting Intimation for Board Meeting Intimation For Consider And Approve Unaudited Financial Results For The Half Year Ended On 30Th September, 2026
- Board meets on 31 Oct 2026 to approve unaudited results for half year ended 30 Sep 2026.
Concalls
-
Nov 2026PPT
Business Profile[1]
Accretion Nutraveda Limited is a healthcare-focused Ayurveda and Nutraceutical CDMO, manufacturing a wide range of Ayurvedic and nutraceutical products across multiple dosage forms for domestic clients, merchant exporters, and direct export customers.